New study confirms Upadacitinib's safety for inflammatory bowel disease in korean patients
NCT ID NCT06459297
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study looked at how safe and effective upadacitinib (RINVOQ) is for Korean adults with moderate to severe ulcerative colitis or Crohn's disease. About 600 participants were followed for up to 52 weeks while taking the drug as prescribed by their doctor. The main goal was to track serious side effects and changes in disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib (RINVOQ)
What this could lead to
If results are positive, this could confirm that upadacitinib is a safe and effective option for managing moderate to severe ulcerative colitis and Crohn's disease in Korean patients.
What could go wrong
This is a post-marketing surveillance study, not a controlled trial, so results may be less definitive. Side effects like serious infections or allergic reactions are possible with upadacitinib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chosun University Hospital /ID# 269990
Gwangju, Jeonranamdo, 61453, South Korea
-
Ewha Womans University Medical Centre /ID# 269776
Seoul, Seoul Teugbyeolsi, 07985, South Korea
-
Gangnam Severance Hospital /ID# 270020
Seoul, Seoul Teugbyeolsi, 06273, South Korea
-
Hallym University Kangnam Sacred Heart Hospital /ID# 270013
Seoul, Seoul Teugbyeolsi, 07441, South Korea
-
Inje University - Ilsan Paik Hospital /ID# 269995
Goyang-si, Gyeonggido, 10380, South Korea
-
Keimyung University Dongsan Hospital /ID# 269775
Daegu, Gyeongsangbuk-do, 42601, South Korea
-
Kyung Hee University Hospital /ID# 270003
Dongdaemun-gu, Seoul Teugbyeolsi, 02447, South Korea
-
Seoul Songdo Hospital /ID# 270009
Junggu, 04597, South Korea
-
SoonChunHyang University Hospital Cheonan /ID# 270015
Cheonan-si, Chungcheongnam-do, 31151, South Korea
-
The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 267843
Daejeon, Daejeon Gwang Yeogsi, 34943, South Korea
-
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 270014
Seoul, Seoul Teugbyeolsi, 06591, South Korea
-
Ulsan University Hospital /ID# 270006
Ulsan, Ulsan Gwang Yeogsi, 44033, South Korea
-
Yeungnam University Medical Center /ID# 269992
Daegu, 42415, South Korea
-
Yonsei University Health System Severance Hospital /ID# 268865
Seoul, Seoul Teugbyeolsi, 03722, South Korea